



## MAJOR SHAREHOLDER ANNOUNCEMENT

July 27, 2012

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has increased its holding of B shares in Novozymes to 7.82%, previously reported at 7.71% (an increase of 0.11%).

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 25,413,977 shares of a nominal value of DKK 50,827,954, equivalent to 7.82% of Novozymes A/S' share capital and 3.14% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, increasing its holding of B shares in Novozymes A/S to a total of 16,327,429 B shares of a nominal value of DKK 32,654,858, equivalent to 5.02% of Novozymes share capital.

### Contact persons:

#### Press and media:

René Tronborg (Europe)  
Tel. (direct): +45 4446 2274  
Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)  
Tel. (direct): +1 919 494 3209  
Tel. (mobile): +1 919 218 4501

#### Investor relations:

Martin Riise  
Tel. (direct): +45 4446 0738  
Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)  
Tel. (direct): +1 919 494 3483  
Tel. (mobile): +1 919 649 2565

*Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at [www.novozymes.com](http://www.novozymes.com).*